USAID negotiating Depo purchase, but shelf life proves problematic

Family Plan World. Jul-Aug 1993;3(4):7, 21.

Abstract

PIP: The discussion focused on the variations in purchasing agreements for the injectable Depo-Provera. Negotiations are in process between the manufacturer in the US (the UpJohn Company) and USAID regarding size of purchase, prices, and time schedules. A glitch is that the US production plant provides a two-year shelf life for the product, while the Belgian plants provide a three-year shelf life. The one year difference could be significant in the distribution to hard-to-reach places, but the balancing point is that USAIDs effort are a positive development for expanding distribution. The UN Population Fund (UNFPA) and the International Planner Parenthood Federation (IPPF) already distribute Depo-Provera and were charged 72 and 75 cents, respectively; UpJohn recently increased the prices to 80 and 85 cents. The UNFPA prices were slightly lower due to larger purchases, and both concerns will be awaiting the outcome of USAID's price negotiations. Other manufacturers are a company in Indonesia, which sells only within the country, and Organon in Holland, which produces the drug under the name Megstron. UpJohn has the major share of the market. The cost of supplying Depo-Provera also includes the purchase of needles and syringes. Other international agencies are not limited by anything other than finding the lowest cost. UNFPA buys its supplies in Belgium at low cost and its contraceptives in Holland. USAID, however, must purchase needles and syringes from American facilities. IPPF will be watching to assure international organizations that no duplication of effort will occur with the USAID distribution and expects the shelf life problem to be resolved. The issue may be cleared up when UpJohn has sufficient time to resubmit its application with enough research to support the 3-year shelf life; the FDA had rejected Depo-Provera repeatedly since 1961, and the approval was granted on a rushed application that only included some of the Belgian research and could empirically only support a 2-year shelf life.

MeSH terms

  • Americas
  • Commerce*
  • Contraception
  • Contraceptive Agents
  • Contraceptive Agents, Female
  • Developed Countries
  • Economics
  • Evaluation Studies as Topic*
  • Family Planning Services
  • Government Agencies*
  • Health Services Accessibility*
  • Injections*
  • International Agencies
  • Medroxyprogesterone Acetate*
  • North America
  • Organizations
  • United Nations*
  • United States

Substances

  • Contraceptive Agents
  • Contraceptive Agents, Female
  • Medroxyprogesterone Acetate